Jackson’s Record Quarter Powers the Bull Case
When U.K.-based Prudential plc (NYSE: PUK) spun off its U.S. annuity business as Jackson Financial (NYSE: JXN) in September 2021, investors might have thought it was a complicated, hand-me-down life insurer. For its first two years, the stock barely moved.
Three years later, that has all changed. A record quarter and a significant leadership transition together make this an important moment to size up whether the company’s rally has more room to run.
With a nearly 30% increase in its stock price this year, investors need to decide whether chasing the stock now is too late for the party.
Record Earnings Drive Momentum
Jackson reported adjusted operating earnings of $513 million, or $7.30 per diluted share for the second quarter, a company record, comfortably ahead of the $5.72 analysts had modeled.
Excluding notable items, adjusted operating earnings per share (EPS) grew 55% year-over-year, powered by strong spread income and a shrinking share count from years of buybacks.
GAAP net income attributable to common shareholders, which can swing with derivative and hedging accounting, came in at $644 million, or $9.16 per diluted share, versus $168 million, or $2.34 per share, a year earlier.
But the GAAP figure is not the number investors most care about. The adjusted operating number, led by sales momentum, is more closely watched.
In that, retail annuity sales came in at $5.9 billion in the quarter, up 34% from a year earlier, while sales of its registered index-linked annuities (RILA) hit a record $2.3 billion, up 69%.
Capital Returns Strengthen the Case
That shift matters because it feeds into capital returns, which is the real heart of the investment case. Jackson returned $290 million to common shareholders in the second quarter alone, split between $227 million of buybacks and $63 million of dividends, a 34% increase from a year earlier. The company has now returned nearly $3.3 billion to shareholders since becoming independent in 2021.
Management reaffirmed its full-year 2026 target of $900 million to $1.1 billion in capital return, building on the $862 million returned in 2025, itself up 47% per share from 2024.
The board also raised the quarterly common dividend 12.5% to 90 cents per share, putting the yield around 2.6%.
Analysts See Limited Upside
Analyst sentiment is more mixed than the stock's chart might suggest. The consensus rating among seven analysts is a Moderate Buy, with one Strong Buy, two Buys, and four Holds. The average 12-month target price is $133.80, about 4% below the current share price.
The highest target is $149 per share, while the lowest is $105. Two analysts have boosted their target price since earnings were released, as one other analyst upgraded the stock.
Leadership Change Adds Risk
There are reasons for caution here, not just profit-taking concerns.
Jackson recently announced that longtime chief executive Laura Prieskorn will retire after nearly 40 years with the company. The company will hand the reins to current chief financial officer Don Cummings at the beginning of October. Leadership transitions at complex insurers always carry execution risk, even those described, as this one was, as an orderly succession.
Jackson's business also remains exposed to equity markets through its large legacy variable annuity book. The company has flagged that a significant market decline could become a headwind.
In addition, Jackson operates in a crowded field of annuity writers, including Lincoln National (NYSE: LNC), Equitable Holdings (NYSE: EQH), Brighthouse Financial (NASDAQ: BHF), Corebridge Financial (NYSE: CRBG) and F&G Annuities & Life (NYSE: FG), all chasing the same retiring-Boomer demand for guaranteed income.
Jackson's edge has been its No. 1 position in traditional variable annuities and near the top in the fast-growing RILA category. That’s been reinforced by a private-credit sourcing partnership with TPG (NASDAQ: TPG) that Jackson said is already improving new-money yields.
The Bull Case Meets a Richer Valuation
For investors, Jackson looks like a value stock for patient investors. Its share count is shrinking and has a growing dividend, double-digit adjusted operating earnings growth, and a business mix becoming less market sensitive.
In general, this is not a flashy growth stock, but a steady compounder that has quietly outperformed while a leadership change and a full valuation catch everyone's attention.
For those considering a position, the analyst consensus price target sitting today's share value below might be a signal to wait for a pullback rather than chase the stock so close to its 52-week high. A few more quarters after the leadership handoff and some additional earnings releases, while watching for net flows and capital ratios, could be the right call before committing new money.
Where Should You Invest $1,000 Right Now?
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
